From WikiProjectMed
(Redirected from Umeclidinium bromide)
Jump to navigation Jump to search
Trade namesIncruse Ellipta
Other namesGSK573719A
  • Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
Clinical data
Drug classLong-acting muscarinic antagonist (LAMA)[1]
Main usesCOPD[1]
  • US: C (Risk not ruled out)
Routes of
Inhalation (DPI)
Typical dose55 to 62.5 ug per day[2][1]
External links
License data
Legal status
  • US: ℞-only
  • In general: ℞ (Prescription only)
Protein binding~89%[3]
MetabolismLiver (CYP2D6)
Elimination half-life11 hours
ExcretionFeces (58%) and urine (22%)
Chemical and physical data
Molar mass508.500 g·mol−1
3D model (JSmol)
  • C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
  • InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1

Umeclidinium, sold under the trade name Incruse Ellipta, is a medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is not used for asthma.[1] It is used by breathing the medication into the lungs.[1]

Side effects may include change in taste, cough, and eye pain.[1][2] Severe side effects may include anaphylaxis, bronchospasm, urinary retention, and glaucoma.[1] It is not recommended in those with severe milk protein allergies.[1] It is a long-acting muscarinic antagonist (LAMA).[1]

Umeclidinium was approved for medical use in the United States in 2014.[1] It is on the World Health Organization's List of Essential Medicines as an alternative to tiotropium.[4] In the United Kingdom a month of medication costs the NHS about £28 while in the United States this amount is about 380 USD.[2][5] It is also available in combination as umeclidinium/vilanterol[1][6] and fluticasone/umeclidinium/vilanterol.[7]

Medical uses

It is used for the long term maintenance of COPD.[2]


It is used once per day at 55 ug or 62.5 ug.[2][1]

Society and culture


This medication for inhalation, has a cost in the U.S. of $88 (USD) for 7 powder 62.5 mcg (0.0625 mg)/inhalations.[8]


  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 "Umeclidinium Monograph for Professionals". Archived from the original on 27 January 2021. Retrieved 13 August 2021.
  2. 2.0 2.1 2.2 2.3 2.4 BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 263. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  3. "Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Archived from the original (PDF) on 10 July 2018. Retrieved 22 February 2016.
  4. World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  5. "Incruse Ellipta Prices, Coupons & Patient Assistance Programs". Archived from the original on 29 August 2021. Retrieved 30 August 2021.
  6. Feldman GJ, Edin A (December 2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects". Therapeutic Advances in Respiratory Disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659. S2CID 5744282.
  7. "TRELEGY ELLIPTA Package Insert" (PDF). GlaxoSmithKline. September 2017. Archived (PDF) from the original on 12 July 2020. Retrieved 11 July 2020.
  8. "Incruse Ellipta Prices, Coupons & Patient Assistance Programs". Archived from the original on 29 August 2021. Retrieved 9 April 2021.

External links